[finviz ticker=NOVN]
EPS Estimates for Novan
Novan, Inc. (NOVN, NASDAQ Novan, Inc. (NASDAQ:NOVN Find Rating) Analysts from research at Cantor Fitzgerald increased their FY2022 earnings estimates per share of Novan in a document released on May 17th, Tuesday. Cantor Fitzgerald analyst J. Kim is now predicting Novan to be able to earn ($2.33) for each share over the year, which is up from their previous estimate for ($2.36).
Novan (NASDAQ: NOVN – Get Rating) recently released its quarterly earnings report on May 16. Novan posted ($0.71) earnings per share for the quarter. It was below estimates for ($0.57) in the amount of ($0.14). Novan reported a negative net margin of 838.95 percent, and the company had a negative return on equity of 165.01 percent. The same quarter in the previous time, it made ($0.60) in earnings per share.
Other analysts from the research field have also recently published reports on the stock. StockNews.com started coverage on the shares Novan in a research paper on March 31, 2014. They gave the company’s price at a “sell” rating for the Novan company. HC Wainwright restated a “buy” rating and established the $24.00 price target for the shares Novan in a research paper on March 15, 2015.
The shares of Novan started trading on the market at $2.79 the previous day. Novan has a one-year lowest that was $2.24 and a one-year maximum of $20.74. Novan has a market capitalization of $53.49 million with a ratio of P/E in the range of -1.48 with a beta that is 0.18. It has a debt-to equity ratio of 2.81 and an average ratio of 1.25 and the quick ratio is 4.85. The company has a fifty-day simple average that is $3.13 and a two-hundred-day easy moving average $3.96.
In other developments director John W. Palmour bought 10,000 shares of the company’s stock on March 18. The shares were purchased for an average cost at $3.63 each, for the total amount of $36,300.00. The transaction was revealed in a formal filing to the Securities & Exchange Commission, which can be accessed via this link. In the past ninety days, insiders have purchased 20000 shares of the company’s stock worth 70,480. Insiders control 1.70 percent from the shares of stock.
Investors from institutions have recently altered their position in Novan. Vanguard Group Inc. lifted its stake within Novan by 1.1 percent during the quarter that began in. Vanguard Group Inc. now holds 789,719 shares of Novan’s stock worth $3,112,000 following the purchase of another 8,899 shares in the same period. Renaissance Technologies LLC raised its stake on shares Novan by 11.1 percent during the initial quarter. Renaissance Technologies LLC now owns 382,665 shares in Novan’s stock, valued at $1,508,000, after having purchased 38,293 more shares over the time. Morgan Stanley raised its holdings in shares of Novan by 16.3 percent during the initial quarter.
Morgan Stanley now owns 258,617 shares of Novan’s stock, valued at $404,000, after buying 36,196 shares in the time. Geode Capital Management LLC raised its holdings of Novan shares Novan by 9.5 percent during the 3rd quarter. Geode Capital Management LLC now holds 134,684 shares in the Novan stock, worth $1,096,000, after the acquisition of an additional 11,721 shares in the past quarter. Additionally, GSA Capital Partners LLP bought a part in the shares of Novan in the first quarter, worth approximately $501,000. 12.95 percent of the shares is held by institutional investors.
Outtake: So, what should you do with this information? What is the stock price of Novan going to be in the near future? Who should invest in Novan? These are all questions that can only be answered by consulting with a financial analyst. Do your own research and due diligence before investing any money into the company. We have provided you with some resources to get started but remember that it is always important to consult with a professional before making any decisions about your finances.
Novan Company Profile
Novan, Inc, a pre-commercial pharmaceutical company based on nitric oxide that focuses on dermatology as well as anti-infective treatments. The company’s dermatology drug candidates comprise SB204 an oral monotherapy that treats acne vulgaris SB206 an antiviral topical cream that is used to treat of skin infections caused by viral infection; SB208 which is a topical broad spectrum anti-fungal gel that is used to treat of fungal infections on the nails and skin including athlete’s foot as well as fungal nail infections. SB414 an topical cream-based gel product that could be used to treat the inflammatory skin diseases.